{"organizations": [], "uuid": "7a1b34d5fca9606a6eea0309f1510343cf71b96f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "", "site_section": "http://www.reuters.com/finance/personal-finance", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "http://www.reuters.com/article/2015/09/24/idUSFWN11T04M20150924", "country": "US", "title": "BRIEF-GSK and Theravance to file Relvar Ellipta for COPD in Japan", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "BRIEF-GSK and Theravance to file Relvar Ellipta for COPD in Japan | Reuters", "spam_score": 0.0, "site_type": "news", "published": "2015-09-24T11:15:00.000+03:00", "replies_count": 0, "uuid": "7a1b34d5fca9606a6eea0309f1510343cf71b96f"}, "author": "Reuters", "url": "http://www.reuters.com/article/2015/09/24/idUSFWN11T04M20150924", "ord_in_thread": 0, "title": "BRIEF-GSK and Theravance to file Relvar Ellipta for COPD in Japan", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Sept 24 Glaxosmithkline Plc :\n* Intention to file Relvar Ellipta for COPD in japan\n* This decision follows results from an additional global phase 3 efficacy and safety study.\n* GSK and Theravance announce intention to file Relvar Ellipta for COPD in Japan\n* Study showed that patients who received FF/VI 100/25mcg achieved a statistically significant improvement in lung function\n* Pneumonia as an adverse event of special interest was reported in 7 subjects in each treatment group\n* Full results from study will be subject of a future publication / presentation.\n* Supplemental Japanese new drug application for Relvar ellipta for treatment of chronic obstructive pulmonary disease with regulator during Q1 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)", "external_links": [], "published": "2015-09-24T11:15:00.000+03:00", "crawled": "2015-09-24T10:34:53.700+03:00", "highlightTitle": ""}